Rana R. McKay, MD

Articles

Emerging Trials and the Future of Biomarker-Driven Therapy in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field toward increasingly complex, biomarker-driven treatment selection.

Choosing a Chemotherapy-Based Triplet Regimen in Metastatic Castration-Sensitive Prostate Cancer

July 9th 2025

Panelists discuss how the ARASENSE and PEACE-1 phase 3 trials demonstrated the efficacy of triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and novel antiandrogens, while addressing the ongoing underutilization of intensified treatment approaches.

Patient Fitness and the Doublet vs Triplet Debate in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how medical comorbidities, physiologic vs chronologic age, drug interactions, and performance status influence the choice between doublet and triplet therapy regimens.

Personalizing Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic biomarkers, guide treatment intensification decisions in metastatic castration-sensitive prostate cancer.

Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

March 4th 2024

Our expert panel provide insightful discussion on the power of multidisciplinary expertise in advanced prostate cancer.

Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

March 4th 2024

Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistant prostate cancer.

Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

February 26th 2024

This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.

Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

February 26th 2024

Expert perspectives on androgen receptor signaling and its role in fueling prostate cancer metastasis along with a whiteboarding animation depicting this process.

Treatment Selection in Metastatic and Castration Resistant Prostate Cancer Optimizing Outcomes and Preserving Patient Quality of Life

February 19th 2024

Drs. Shore & McKay discuss treatment selection for metastatic & castration-resistant prostate cancer, the current landscape, and key factors guiding personalized treatment decisions.

Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

February 19th 2024

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice

Metastatic Prostate Cancer: Background and Patient Prognosis

December 20th 2023

An expert provides an overview of metastatic prostate cancer, including information on how it advances, patient prognosis, and what factors influence outcomes.

Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs

December 18th 2023

Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.

Data from the DEAR Real-World Study and Strategies for Optimizing Outcomes

December 18th 2023

Drs. Dorff and McKay discuss real-world data from DEAR trial comparing darolutamide, enzalutamide and apalutamide, providing clinical pearls on their experiences to optimize outcomes.

Evolving Insights into Castration Resistance: Novel Biomarkers Predicting Disease Progression

December 15th 2023

Dr. Tanya Dorff and Dr. Rana McKay discuss the mechanisms driving castration resistance and how emerging epigenetic biomarkers may transform prognosis.

Evolving Paradigms in the Detection and Treatment of Prostate Cancer

December 15th 2023

Expert oncologists offer insights into conquering resistance, reimagining screening, and realizing the paradigm-shifting potential of advances in biomarker-driven precision medicine.

Considerations When Treating Patients With Metastatic Renal Cell Carcinoma

January 17th 2023

Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.

Dr. McKay on Future Directions For mRCC Research

November 16th 2022

Rana R. McKay, MD, discusses the potential impact of triplet therapies in the treatment paradigm for metastatic renal cell carcinoma and identifies several other areas for further study.

Future Directions in the Management of Renal Cell Carcinoma

November 10th 2022

Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.

Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma

November 10th 2022

Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.

Dr. McKay on Tivozanib Plus Nivolumab in Advanced RCC

November 4th 2022

Rana R. McKay, MD, discusses the rationale for combining tivozanib with nivolumab in heavily pretreated patients with renal cell carcinoma.